Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
The analysis uncovered established subtypes and added new classifications, while also identifying a potential new treatment target.
The projects, set to begin this year, concern prostate cancer, infectious diseases, rheumatoid arthritis, inflammatory bowel disease, heart disease, and sleep disorders.
In PLOS this week: map of breakpoints in individuals with complex chromosomal rearrangements, sequence of virus that infects African armyworm, and more.
DNA sequence data from hundreds of individuals suggest that age, smoking, and alcohol use coincide with the expansion of clones containing NOTCH1 and PPM1D mutations.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
Investigators showed that sequencing cell-free DNA could detect microsatellite instability, structural rearrangements, and clonal hematopoiesis in patients with metastatic disease.
Using single-cell RNA sequencing and lineage tracing in a mouse model, researchers followed skin stem cell expression patterns in response to skin injury.
The University of Texas MD Anderson Cancer Center's James Allison and Kyoto University's Tasuku Honjo have won this year's Nobel Prize in Physiology or Medicine.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.